Precision BioSciences

113 articles with Precision BioSciences

• Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

  1/19/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS® genome editing platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR19B, a next-generation, stealth cell,

• Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that Matt Kane, Co-founder and Chief Executive Officer and Derek Jantz, Ph.D., Co-Founder and Chief Scientific Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference

• Precision BioSciences Announces Executive Leadership Change

  12/14/2020

  Precision BioSciences, Inc. a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that Abid Ansari, Chief Financial Officer, notified the Company that he will be leaving the organization after nearly five years to pursue a new career opportunity.

• Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

  12/4/2020

  Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced positive interim clinical results from its Phase 1/2a study of PBCAR0191, the Company’s off-the-shelf allogeneic CAR T cell therapy investigational candidate targeting CD19.

• Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.

• Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

  11/20/2020

  Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

• 

  Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?

  11/20/2020

  Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement.

• Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/10/2020

  Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors

• Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020

  11/3/2020

  Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020.

• Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T PatentsPTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings

  10/15/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision.

• Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer

  10/14/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that Alex Kelly has been appointed to the newly created position of Chief Corporate Affairs Officer.

• Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October 2020

  9/28/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced its participation in the following upcoming virtual investor conferences:

• 

  Clinical Catch-Up: September 21-25

  9/28/2020

  The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

• Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

  9/21/2020

  Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product

• Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

  9/17/2020

  Precision BioSciences, Inc. announced the companies have added two additional hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement.

• Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma

  9/9/2020

  Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma.

• Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September 2020

  9/2/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced its participation in the following upcoming investor conferences:

• Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy

  8/19/2020

  Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia.

• Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/13/2020

  Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma

• Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences

  8/3/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced it will report financial results for the second quarter of 2020 on August 13, 2020.